Anti-TIM-3 Antibodies for Reversing Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting TIM-3 signaling have limitations in effectively antagonizing TIM-3-mediated immune suppression, which can modulate immune responses in diseases such as cancer and infectious diseases.
Innovation Solution
Development of antibodies that specifically bind to human TIM-3 and antagonize its function, increasing T cell activation and reducing Treg-mediated immune suppression, thereby treating cancer and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current TIM-3 signaling therapies are used, then treatment can be administered, but effectiveness in antagonizing TIM-3-mediated immune suppression is limited
Solution Approach 1:
The patent employs parameter changes by modifying antibody structures (humanized, chimeric, monoclonal variants) and their binding affinities to TIM-3 to enhance therapeutic effectiveness. Different antibody formats (IgG1, IgG2, IgG4 subclasses) are used to optimize pharmacokinetic and pharmacodynamic parameters, thereby improving reliability of TIM-3 antagonism while maintaining manageable therapy complexity
Solution Approach 2:
The patent develops universal anti-TIM-3 antibody molecules that can function across multiple disease indications (cancer, infectious diseases, autoimmune disorders) and can be used in various therapeutic contexts (monotherapy, combination therapy). This multi-functionality approach improves reliability by providing a versatile tool that addresses TIM-3-mediated immune suppression in diverse pathological conditions without requiring disease-specific modifications
2Productivity
If TIM-3-mediated immune suppression is not effectively antagonized, then immune responses remain modulated in diseases, but therapeutic intervention fails to activate sufficient T cell response
Solution Approach 1:
The patent applies preliminary anti-action by using anti-TIM-3 antibodies to block the inhibitory TIM-3 signaling pathway before it can suppress T cell activation. By preemptively antagonizing TIM-3 receptors on T cells and other immune cells, the therapy prevents the harmful immune suppression from occurring, thereby enabling sufficient T cell activation to mount effective immune responses against tumors or pathogens
Solution Approach 2:
The patent converts the harmful effect of TIM-3-mediated immune suppression into a beneficial therapeutic outcome by using anti-TIM-3 antibodies to reverse the suppressive signaling. The same TIM-3 pathway that normally downregulates immune responses is targeted to unleash enhanced T cell activation and cytotoxicity, transforming the harmful immune tolerance into beneficial anti-tumor or anti-infectious immunity
Data Source
Figure 1
Figure 2A~2B
Figure 3A
AI summary
The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.